Adjunctive Perampanel Oral Suspension in Pediatric Patients From ≥2 to <12 Years of Age With Epilepsy: Pharmacokinetics, Safety, Tolerability, and Efficacy

Study 232, an open-label pilot study with an extension phase, evaluated the pharmacokinetics and preliminary safety/tolerability and efficacy of adjunctive perampanel oral suspension (≤0.18 mg/kg/d) in epilepsy patients aged ≥2 to <12 years. Patients were grouped into cohorts 1 (aged ≥7 to <12...

Descripción completa

Detalles Bibliográficos
Autores principales: Renfroe, J. Ben, Mintz, Mark, Davis, Ronald, Ferreira, Jose, Dispoto, Sharon, Ferry, Jim, Umetsu, Yuko, Rege, Bhaskar, Majid, Oneeb, Hussein, Ziad, Laurenza, Antonio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6444512/
https://www.ncbi.nlm.nih.gov/pubmed/30739576
http://dx.doi.org/10.1177/0883073819827407

Ejemplares similares

Ejemplares similares